Adult Nasal Type Extranodal NK/T-Cell Lymphoma
Oncology·MeSH: Lymphoma, Extranodal NK-T-Cell
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| Vorinostat | Merus N.V. (MRUS) |
Frequently asked questions
How many drugs are in development for Adult Nasal Type Extranodal NK/T-Cell Lymphoma?
BioSniper tracks 1 drug in development for Adult Nasal Type Extranodal NK/T-Cell Lymphoma across 1 company.
How many clinical trials target Adult Nasal Type Extranodal NK/T-Cell Lymphoma?
There are 1 clinical trial targeting Adult Nasal Type Extranodal NK/T-Cell Lymphoma tracked by BioSniper.
What is the prevalence of Adult Nasal Type Extranodal NK/T-Cell Lymphoma?
The estimated prevalence of Adult Nasal Type Extranodal NK/T-Cell Lymphoma is approximately 56.0 per 100,000 population.
Deep-dive into Adult Nasal Type Extranodal NK/T-Cell Lymphoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis